Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ImmunoFrontier Inc.
DescriptionCancer vaccine consisting of a recombinant protein of melanoma-associated antigen 4 and a polysaccharide-based delivery system (cholesteryl pullulan)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today